866-997-4948(US-Canada Toll Free)

Hypereosinophilic Syndrome - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 60 Pages

Hypereosinophilic Syndrome - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Hypereosinophilic Syndrome - Pipeline Review, H2 2017, provides an overview of the Hypereosinophilic Syndrome (Hematological Disorders) pipeline landscape.

"The hypereosinophilic syndrome (HES) is a disease characterized by a persistently elevated eosinophil count ( 1500 eosinophils/mm) in the blood for at least six months without any recognizable cause, with involvement of either the heart, nervous system, or bone marrow. HES is a diagnosis of exclusion, after clonal eosinophilia (such as leukemia) and reactive eosinophilia (in response to infection, autoimmune disease, atopy, hypoadrenalism, tropical eosinophilia, or cancer) have been ruled out."

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Hypereosinophilic Syndrome - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hypereosinophilic Syndrome (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypereosinophilic Syndrome (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypereosinophilic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III and Phase II stages are 1 and 4 respectively.

Hypereosinophilic Syndrome (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypereosinophilic Syndrome (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Hypereosinophilic Syndrome (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypereosinophilic Syndrome (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypereosinophilic Syndrome (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypereosinophilic Syndrome (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypereosinophilic Syndrome (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypereosinophilic Syndrome (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Hypereosinophilic Syndrome - Overview 5
Hypereosinophilic Syndrome - Therapeutics Development 6
Pipeline Overview 6
Pipeline by Companies 7
Products under Development by Companies 8
Hypereosinophilic Syndrome - Therapeutics Assessment 9
Assessment by Target 9
Assessment by Mechanism of Action 11
Assessment by Route of Administration 13
Assessment by Molecule Type 15
Hypereosinophilic Syndrome - Companies Involved in Therapeutics Development 17
Bristol-Myers Squibb Co 17
GlaxoSmithKline Plc 17
Knopp Biosciences LLC 18
Kyowa Hakko Kirin Co Ltd 18
Stemline Therapeutics Inc 19
Hypereosinophilic Syndrome - Drug Profiles 20
benralizumab - Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
dasatinib - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
dexpramipexole dihydrochloride - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
mepolizumab - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
SL-401 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Hypereosinophilic Syndrome - Dormant Projects 52
Hypereosinophilic Syndrome - Product Development Milestones 53
Featured News & Press Releases 53
Mar 31, 2017: GSK starts phase III study with mepolizumab in patients with severe hypereosinophilic syndrome 53
Mar 21, 2017: Knopp Biosciences Announces Election of Biotech Executive Shane Kovacs to Board of Managers 54
Mar 07, 2017: Knopp Biosciences Announces Publication of Eosinophil-Lowering Effects of Dexpramipexole in Multiple Clinical Trials 54
Jan 04, 2017: Knopp Biosciences Receives Key Patent Directed to Treatment for Hypereosinophilic Syndromes, Asthma, and Other Eosinophilic Diseases 55
Dec 14, 2016: Steroid-Sparing Effects of Dexpramipexole in Hypereosinophilic Syndromes (HES) Reported at American Society of Hematology 2016 Annual Meeting 56
Mar 13, 2014: Knopp Biosciences Broadens Collaboration with NIH to Investigate Eosinophil-Lowering Effects of Dexpramipexole 57
Jan 08, 2014: Knopp Biosciences and NIH to Collaborate in Evaluating Dexpramipexole in Patients with Hypereosinophilic Syndrome 57
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 59
Disclaimer 60

List of Tables
Number of Products under Development for Hypereosinophilic Syndrome, H2 2017 6
Number of Products under Development by Companies, H2 2017 7
Products under Development by Companies, H2 2017 8
Number of Products by Stage and Target, H2 2017 10
Number of Products by Stage and Mechanism of Action, H2 2017 12
Number of Products by Stage and Route of Administration, H2 2017 14
Number of Products by Stage and Molecule Type, H2 2017 16
Hypereosinophilic Syndrome - Pipeline by Bristol-Myers Squibb Co, H2 2017 17
Hypereosinophilic Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2017 18
Hypereosinophilic Syndrome - Pipeline by Knopp Biosciences LLC, H2 2017 18
Hypereosinophilic Syndrome - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017 18
Hypereosinophilic Syndrome - Pipeline by Stemline Therapeutics Inc, H2 2017 19
Hypereosinophilic Syndrome - Dormant Projects, H2 2017 52

List of Figures
Number of Products under Development for Hypereosinophilic Syndrome, H2 2017 6
Number of Products under Development by Companies, H2 2017 7
Number of Products by Top 10 Targets, H2 2017 9
Number of Products by Stage and Top 10 Targets, H2 2017 9
Number of Products by Top 10 Mechanism of Actions, H2 2017 11
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 11
Number of Products by Routes of Administration, H2 2017 13
Number of Products by Stage and Routes of Administration, H2 2017 13
Number of Products by Molecule Types, H2 2017 15
Number of Products by Stage and Molecule Types, H2 2017 15

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *